The Investor
28 Apr 2026, 18:10
Abbott Laboratories announced it has received U.S. FDA clearance and CE Mark approval for its next-generation Ultreon 3.0 AI-powered coronary imaging platform.
The system combines optical coherence tomography (OCT) imaging with AI-driven insights to help physicians better assess arterial blockages and optimize stent placement during minimally invasive heart procedures. The platform enables real-time decision-making, improved accuracy, and faster workflows, aiming to enhance patient outcomes in complex coronary artery disease cases.
Abbott highlighted that the technology provides high-resolution imaging and automated analysis, supporting more precise and efficient treatment planning for procedures such as percutaneous coronary intervention (PCI).
Source: Abbott press release, PRNewswire
The system combines optical coherence tomography (OCT) imaging with AI-driven insights to help physicians better assess arterial blockages and optimize stent placement during minimally invasive heart procedures. The platform enables real-time decision-making, improved accuracy, and faster workflows, aiming to enhance patient outcomes in complex coronary artery disease cases.
Abbott highlighted that the technology provides high-resolution imaging and automated analysis, supporting more precise and efficient treatment planning for procedures such as percutaneous coronary intervention (PCI).
Source: Abbott press release, PRNewswire
